Related to TG Therapeutics Licenses mAb-Based Drug to LFB Biotechnologies

• Abbott Pays Biotest $85M Up Front in Deal for Phase II mAb Against RA and Psoriasis
  
• Apeiron Gains Rights to Phase III-Stage Neuroblastoma Treatment
  
• Lack of Partner Prompts Genmab to Sideline Late-Stage Cancer Antibody
  
• BMS Pays Innate Pharma $35M Up Front for Global Rights to Clinical-Stage Cancer mAb
  
• Sanofi and Genzyme Report Positive Data from Pivotal Trial Comparing Alemtuzumab with Rebif in MS
  
• Amgen Pays $10M Up Front in Cancer Deal with Micromet
  
• EC Clears HGS and GSK’s Systemic Lupus Erythematosus Antibody Therapy Benlysta
  
• Amgen’s Xgeva Approved by EC for Treating SREs in Adults with Solid Tumor-Related Bone Metastases
  
• Sorrento Wins Second NIAID Grant of $600K to Develop Qourum Quenching Antibacterial
  
• French Firm AAA Acquires Dompe’s Radiolabeled mAb for Ovarian Cancer Therapy
  
• EC Approves Roche’s RoActemra for Treating Active Systemic Juvenile Idiopathic Arthritis
  
• Genentech Takes Another Shot at Convincing FDA to Maintain Avastin’s Metastatic Breast Cancer Approval
  
• Pilot Clinical Trial Shows Engineered Autologous T-Cell Therapy Eradicates CLL
  
• FDA Sanctions Abbott's Genetic FISH Panel for Leukemia Prognosis
  
• Oncobiologics and Fox Chase Cancer Center Ally to Develop Cancer Therapy Platform
  
• FDA Issues Novartis with CRL Requesting Additional Safety Data on Gouty Arthritis Drug
  
• F-Star and Merck Serono Sign Potential €492M Deal for Antibody-Derived Therapeutics
  
• Sucampo Taps Numab for Antibody Discovery and Development Expertise
  
• Swiss Institute Spins Out Human mAb Therapeutics Firm
  
• Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data